Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2008; 29(01): 8-15
DOI: 10.4103/0971-5851.51441
Original Article

Post-treatment testicular activity in lymphoma patients

Mushtaq Ahmad
Department of Medical Oncology, Soura, Post Bag. 27, Sheri Kashmir Institute of Medical Sciences, Srinagar, India
,
Abdul Rashid Lone
Department of Medical Oncology, Soura, Post Bag. 27, Sheri Kashmir Institute of Medical Sciences, Srinagar, India
,
Sana Ullah Kuchai
Department of Radiation Oncology, Soura, Post Bag. 27, Sheri Kashmir Institute of Medical Sciences, Srinagar, India
,
Abdul Hamid Zargar
Department of Endocrinology, Soura, Post Bag. 27, Sheri Kashmir Institute of Medical Sciences, Srinagar, India
,
Sheikh Aejaz Aziz
Department of Medical Oncology, Soura, Post Bag. 27, Sheri Kashmir Institute of Medical Sciences, Srinagar, India
,
Gul Mohammad Bhat
Department of Medical Oncology, Soura, Post Bag. 27, Sheri Kashmir Institute of Medical Sciences, Srinagar, India
,
Manzoor A Banday
Department of Medical Oncology, Soura, Post Bag. 27, Sheri Kashmir Institute of Medical Sciences, Srinagar, India
,
Samoon Jelani
Department of Clinical Hematology ,Soura, Post Bag. 27, Soura, Post Bag. 27, Sheri Kashmir Institute of Medical Sciences, Srinagar, India
,
Javid Rasool Bhat
Department of Clinical Hematology ,Soura, Post Bag. 27, Soura, Post Bag. 27, Sheri Kashmir Institute of Medical Sciences, Srinagar, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Objectives: For young patients receiving cancer chemotherapy, the major concern is gonadal dysfunction with impaired reproductive capacity. The impact of such therapy in patients with lymphoma was focus of this study. Methods : Semen analysis and serum FSH and LH levels were determined pretreatment, immediately after completion of therapy and at follow-up in 60 patients of lymphoma receiving chemotherapy. Results : Pretreatment infertility was present in 13.2% of patients. After completion of treatment, 76.9% developed azoospermia. However, after a mean follow up of 56.66 months, percentage of normospermic patients declined to 43.3%, recovery being better in patients of age less than 30 years. Conclusion : The effects of chemotherapy on testicular activity were significant with combination containing cyclophosphamide and procarbazine. Recovery in spermatogenesis and FSH levels to normal was seen in patients receiving cyclophosphamide, vincristine and prednisolone but was least when procarbazine was added to this. 90% patients continued to have azoospermia at 5 years in the group which received cyclophosphamide in combination with procarbazine.



Publication History

Article published online:
07 March 2022

© 2008. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Meistrich ML: Critical components of testicular function and sensitivity to disruption. Biol Reprod 1986;34:17-28.
  • 2 Howell SJ, Shalet SM: Testicular functions following chemotherapy. Hum Reprod Update 2001;7(4):363-9.
  • 3 Bahadur G, Oturk O, Muneer A et al: Semen quality before and after gonad toxic treatment. Hum Reprod 2005;20(3):774-81.
  • 4 Jeff E. Fegan and Larry I, Lipshultz, M.D: Abnormalities of the testes leading to male infertility: Evaluation and diagnosis. Hospimedica 1988;6(1):33-40.
  • 5 Relander T, Cavaltin Stahl E, Garwikz S et al: Gonadal and sexual function in men treated for childhood cancer. Med Paediatr Oncol 2000;35(1):52-63.
  • 6 Dubey P, Wilson G, Mathur KK et al: Recovery of sperm production following radiation therapy after induction chemotherapy with Mitoxantrone, Vincristine, Vinblastine and Prednisone (NOVP). Int J Radiation Oncology Bio Phys 2000;46(3):609-617.
  • 7 Gaudini L, Lambardo F, Salacone P et al: Testicular cancer and Hodgkins disease: evaluation of semen quality. Hum Reprod Update 2003; 18(4):796-801.
  • 8 Whitehead E, Shalet SM, Blackledge G, et al: The effects of Hodgkin′s disease and combination chemotherapy on gonadal function in adult male. Cancer 1982;49:418- 422.
  • 9 Vigersky RA, Chapman RM, Berenberg J, et al: Testicular function in untreated Hodgkin′s disease. Am J Med 1982;73:482-486.
  • 10 Kreuser ED, Xiros N, Hetzel WD, et al: Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin′s disease. J Cancer Res Clin Oncol 1987;113:260-266.
  • 11 Charak B.S , Gupta Rahul, Mandrekar Pranto et al: Testicular dysfunction after cyclophosphamide, vincristine, procarbazine, prednisolone chemotherapy for advanced Hodgkin′s disease. Cancer 1990;65:1903- 1906.
  • 12 Chapman RM: Gonadal effects of chemotherapy in men and boys. Chemotherapy Source Book.Edition first (1992). Editor: Perry M.C: Pub: William′s& Wilkins USA, 730-752.
  • 13 Roeser HP, Stocks AR, Smith AJ: Testicular damage due to cytotoxic drugs and recovery after cessation of therapy. Aust NZJ Med 1978; 8:250-254.
  • 14 Hsu AC, Folami AO, Bain J, et al: Gonadal function in males treated with cyclophosphamide for nephrotic syndrome. Fertil Steril 1979;31:173-177.
  • 15 Buchanan JD, Fairly KF, Barrie JU: Return of spermatogenesis after stopping cyclophosphamide therapy. Lancet 1975;2:156-157.
  • 16 Ettledorf JN, West CD, Pitcock JA, et al: Gonadal function, testicular histology and meiosis following cyclophosphamide therapy in patients with nephrotic syndrome. J Pediatr 1976;88:206-212.
  • 17 Navsmith TE, Blake DA, Harner VJ et al: Do men undergoing sterilizing cancer treatments have a fertile future? Hum Reprod 1998;13(11):3230-5.
  • 18 daCunha MF, Meistrich ML, Fuller LM et al: Recovery of spermatogenesis after treatment for Hodgkin′s disease. Limiting dose of MOPP chemotherapy. J Clin Oncol 1984;2(6):571-577.
  • 19 Lopez Andreu JA, Pernandez PJ, Ferrisi Torlajada J et al: Persistent altered spermatogenesis in long term childhood cancer survivors. Paediatr Haematol Oncol 2000;17(1):21-30.
  • 20 Rodger M. Pryzant, Marvin L Meistrich, Gene Wilson, et al: Long term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin′s lymphomas. J Clin Oncol 1993;11:2:239- 247.
  • 21 Bonnadona G, Santoro A, Viviani S, et al: Treatment strategies for Hodgkin′s lymphoma. Semin Hemat 1988;25(2):51-57.
  • 22 Richard J Sherins and Vincent T. Devita: Effect of drug treatment for lymphoma on male reproductive capacity. Ann Int Med 1973;79:216-220.
  • 23 Chapman RA, Sutcliffe SB. Rees LH, et al. Cyclical combination chemotherapy and gonadal function. Retrospective study in males. Lancet 1979;1:285-289.
  • 24 Chapman RM, Sutcliffe SB, Malpas JS: Male gonadal dysfunction in Hodgkin′s disease. A prospective study. JAMA 1991;245:1323-1328.